Jeff Hall

In a recent interview at the RSNA conference, Roland Rott shared his perspective on the planned acquisition of Intelerad by GE HealthCare along with insights on key synergies and future directions.

In a recent interview at the RSNA conference, Manisha Bahl, M.D., discussed new research examining the use of slab reconstruction technology with digital breast tomosynthesis (DBT), and its potential in reducing interpretation time and imaging volume.

In a recent interview at the RSNA conference, Talissa Altes, M.D., and Konstanze Diefenbach, M.D., discussed the potential utility and recent research findings on the use of the MRI contrast agent gadoquatrane for pediatric patients.

For men with a 1 μg/m3 increase in ten-year exposure to fine particulate matter, a common air pollutant, there was a 47 increased likelihood of moving to a higher CAD-RADS stenosis category, according to new coronary CT angiography research presented at the Radiological Society of North America (RSNA) conference.

The Breast Suite software reportedly provides automated localization of regions of interest on mammograms as well as AI-enabled assessments of breast density and stratification of breast cancer risk for up to two years.

Absent flow to perforator vessels in the face occurred in over 40 percent of women who had cosmetic fillers, according to new vascular ultrasound research presented at the RSNA conference.

Preliminary research has shown that the Vanquish Water Vapor Ablation System eliminated MRI-visible intermediate-risk PCa in over 90 percent of patients.

The Resona A20 device reportedly provides advances in imaging and AI automation along with an intuitive ergonomic design for ease of use.

In a recent interview at the RSNA conference, Constance Lehman, M.D., Ph.D., discussed new research, which compared image-based AI for mammography versus breast density assessment in evaluating breast cancer risk.

The addition of ClearCEM to Mammomat B.brilliant devices reportedly enhances differentiation of suspicious areas in image reconstruction and facilitates improved accuracy with tomosynthesis-guided biopsies.

In a recent interview, Stamatia Destounis, M.D., discussed new research, which showed that over 20 percent of breast cancer was detected in women under 50 years of age and that 80 percent of these cases involved invasive breast cancer.

Reportedly the first MRI platform with a helium-free 3T magnet, the BlueSeal Horizon device offers a variety of AI-powered features as well as enhanced 3D image reconstruction.

In a study of over 13,000 patients who presented with knee pain, MRI data demonstrated a 20 percent higher prevalence of anterior cruciate ligament (ACL) tears in men than women.

Catch up on the top radiology content of the past week.

The new FDA 510(k) clearances for RapidAI include Rapid LMVO, which facilitates assessment of ischemic stroke, and Rapid MLS, which aids in the quantification of midline shifts with potential brain injuries.

Utilizing the AI-enabled TrackPSMA to monitor the effectiveness of radioligand therapy for prostate cancer may allow more timely decisions to adjust treatment dosage or switch to a more effective modality.

Deep learning assessment of adrenal gland volume on computed tomography (CT) scans may provide an objective assessment of chronic stress with significant links to adverse cardiovascular outcomes, according to new research to be presented at the Radiological Society of North America (RSNA) annual meeting.

In a recent interview, Nina Kottler, M.D., discussed key trends that are leading to a renewed focus on improved enterprise imaging platforms and the potential promise of integrating Cognita Imaging’s Mosaic Drafting vision language model technology into the MosaicOS platform.

Combining AI advances and ergonomic innovation, the R20 ultrasound platform reportedly offers a variety of automated tools and design features to facilitate a smoother, efficient imaging workflow.

In MRI findings to be presented at the upcoming RSNA meeting, researchers demonstrated that the combination of higher muscle mass and lower visceral fat may have an impact on brain aging.

Catch up on the top radiology content of the past week.

Comparing annual emergency department encounters that involved a head CT in 2007 and 2022, researchers noted a 51 percent increase and also found significant disparities in access to head CTs for Black patients, those on Medicaid and patients in rural hospital settings.

Geared toward interventional radiologists, the Alphenix 4D CT with Aquilion One/Insight Edition combines angiography capabilities with advanced features in computed tomography.

For T3-T4 rectal cancer staging, a new study showed that optimal photon-counting CT offered an AUC range between 80 and 86 percent in comparison to an AUC range between 78 and 88 percent for rectal MRI.

The recently launched PIV Assist reportedly offers a variety of features including real-time calculation of the catheter-to-vein ratio and pre-scan differentiation of veins and arteries to facilitate vascular access planning.

The use of radiomics for mammography may help predict the development of occult invasive cancer in women with ductal carcinoma in situ (DCIS), according to a new study.

In a recent interview, Christoph Lee, M.D., discussed key findings from the ASSURE study, which evaluated the use of AI in detection and triage in a multicenter trial involving over 579,000 women who had digital breast tomosynthesis (DBT) exams.

The Synapse One platform reportedly offers a variety of enterprise imaging capabilities and may facilitate reduced third-party integration complexities and costs.

Along with the capability of automated measurements and 3D reconstructions of the aorta, Rapid Aortic may facilitate earlier detection of aortic aneurysms and dissections on computed tomography exams.

Incorporating mpMRI radiomics, clinical characteristics, deep learning and pathomic features, a multimodal model offered 82 percent and 87 percent AUCs for predicting overall survival outcomes at five years and seven years, respectively, for women treated with neoadjuvant chemotherapy for breast cancer.